Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06740799 · ClinicalTrials.gov registry record · Phase 1
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
A Phase 1 study of Hepatic Impairment, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT06740799: Recruiting Phase 1 study of Hepatic Impairment, sponsored by Daiichi Sankyo.
NCT06740799 is a Phase 1 study of Hepatic Impairment that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 12 participants, below the 36-participant average among 48 other Hepatic Impairment trials with a reported enrollment target (67% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06740799, a Phase 1 study of Hepatic Impairment, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will evaluate and compare the PK in subjects with severe HI to that of matched healthy control subjects with normal hepatic function.
Primary Outcome
Maximum concentration, determined directly from individual concentration-time data
Conditions Studied
Interventions
- DRUG Quizartinib
Study Locations (3)
Florida
- Clinical Pharmacology of Miami, LLC - Miami
- Advanced Pharma - Miami
- GCP Research - St. Petersburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 1 |
What NCT06740799 shows while recruiting
NCT06740799 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 36-participant average among 48 other Hepatic Impairment trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Hepatic Impairment appearing as the primary indexed condition, and to 1 intervention - of which Quizartinib is the first listed.
NCT06740799 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06740799 about?
NCT06740799 is a clinical study titled "Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment". This study will evaluate and compare the PK in subjects with severe HI to that of matched healthy control subjects with normal hepatic function.
What is the current status of trial NCT06740799?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-09-30. Estimated completion is 2026-03-01.
What conditions does trial NCT06740799 study?
This clinical trial studies the following conditions: Hepatic Impairment.
What interventions are being tested in trial NCT06740799?
The interventions under investigation include: Quizartinib (DRUG).
Who is sponsoring clinical trial NCT06740799?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06740799 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06740799's enrollment target sits among peer trials
12 49th of 48 the lowest of 48 other Hepatic Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatic Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
RECRUITING · Phase 1
-
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
RECRUITING · Phase 1
-
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
RECRUITING · Phase 1
-
A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI